At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
MM-121 +4 moredrug
Likely dose
MM-121 20 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating MM-121, Carboplatin, and 3 other interventions for Solid Tumors. Completed, enrolled 43 participants across 5 sites in 2 countries.
Detailed Summary
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesFrance, United States
CollaboratorsSanofi
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionNov 2013
Study CompletionJan 2014
TodayJul 2026
First PostedOct 6, 2011
Enrollment StartOct 1, 2011
Primary CompletionNov 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.7 years ago
Interventions
MM-121drug
MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
Carboplatindrug
administered at AUC 6
Pemetrexeddrug
administered IV at 500 mg/m2
Cabazitaxeldrug
administered IV at 20 mg/m2 or 25 mg/m2
Gemcitabinedrug
administered IV at 1000 mg/m2 or 1250 mg/m2